Amgen has launched a new direct-to-consumer (DTC) platform, AmgenNow, offering its cholesterol-lowering drug Repatha at a substantially reduced price. The initiative was introduced as part of a broader response among pharmaceutical companies to President Donald Trump’s call for expanded DTC options aimed at reducing prescription drug costs in the United States.
Through AmgenNow, Repatha will be available to patients for $239 per month, which is nearly 60% below its list price of $572.70. Amgen said this represents the lowest direct-to-patient price for Repatha among the G7 advanced economies.
The company described the discount as being offered “in support of the Trump Administration’s efforts to lower drug prices for Americans” and noted that AmgenNow will also be accessible through the federal government’s upcoming TrumpRx platform, expected to launch in 2026.
Amgen said the program is open not only to uninsured patients but also to individuals in high-deductible health plans and those who prefer to pay cash or out of pocket. Purchases made through the AmgenNow portal will not involve insurance coverage. “Amgen is committed to finding new ways to help patients benefit from our medicines,” said Murdo Gordon, the company’s executive vice president of global commercial operations. “The AmgenNow program will allow even more Americans at increased risk of major adverse cardiovascular events to benefit from this effective medicine.”
The company added that the $239 monthly price will also be available through a collaboration with GoodRx at more than 70,000 pharmacies across the United States, giving patients an additional option for purchasing Repatha at the same reduced price.
Amgen is the only major pharmaceutical company so far to directly reference President Trump in its DTC announcement. Other companies, including Bristol Myers Squibb, AstraZeneca, Novartis, and Boehringer Ingelheim, have recently announced similar programs but without citing the administration’s initiative.
The launch follows a July letter from President Trump to 17 major drugmakers, including Amgen, urging them to align U.S. prices with those in other high-income countries, establish direct-to-consumer purchasing channels, and expand investment in the United States. Trump warned that companies failing to comply could face 100% tariffs on branded drugs.
Amgen stated that the $239 price matches the lowest rate the company receives in any economically developed market. The company also said it intends to add more medicines to the AmgenNow platform in the future.
Repatha, an injected drug that targets PCSK9, a protein involved in maintaining LDL cholesterol levels, generated $2.2 billion in sales last year. It is prescribed for patients who do not achieve adequate cholesterol control with statin medications.
The AmgenNow launch comes shortly after Amgen reported late-stage trial results involving more than 12,000 high-risk patients who had not experienced prior heart attacks or strokes. The study found that Repatha significantly reduced the risk of major adverse cardiovascular events compared with standard care. The data followed an FDA label expansion in August, allowing Repatha’s use for primary prevention in adults with uncontrolled LDL cholesterol at increased cardiovascular risk.
Amgen said that patients purchasing Repatha through AmgenNow will not be subject to prior authorization or step therapy requirements, which are commonly applied by insurers. The company described the new platform as a way to expand patient access to its medicines through direct purchasing options.
